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Deletions of the long arm of chromosome 10 have been described
in many tumour types, including carcinoma of the prostate, uterus,
glioblastoma, meningioma and melanoma (Rasheed et al, 1992;
Isshiki et al, 1993; Rempel et al, 1993; Jones et al, 1994; Gray
et al, 1995; Cairns et al, 1997). Recently, loss of heterozygosity
(LOH) of 10q has been reported in bladder tumours (Cappellen
et al, 1997; Kagan et al, 1998), confirming previous cytogenetic
reports of monosomy 10 and 10q deletion (Gibas et al, 1984; Atkin
and Baker, 1985; Berger et al, 1986; Babu et al, 1987; Smeets et al,
1987) and comparative genomic hybridization and fluorescence in
situ hybridization studies (Kallioniemi et al, 1992; Wang et al,
1994). A critical region of deletion defined in these studies is coin-
cident with the major region mapped in other tumour types.
Recently, the PTEN/MMAC1 gene was identified as a candidate
tumour suppressor gene within this region at 10q23
(Li et al, 1997; Steck et al, 1997). Mutations of PTEN have been
described in glioblastomas (Rasheed et al, 1992; Wang et al, 1994;
Cairns et al, 1997; Steck et al, 1997), carcinomas of the prostate
(Steck et al, 1997) and breast (Rhei et al, 1997), endometrial carci-
noma (Risinger et al, 1997) and melanoma (Guldberg et al, 1997),
indicating that PTEN is the likely target of deletions in these cases.
Recently, a low frequency of PTEN mutation has been reported
in bladder cancer (Cairns et al, 1998). In addition, germline muta-
tions of PTEN are present in the familial cancer predisposition
syndromes Cowden disease, Lhermite–Duclos disease and
Bannayan–Zonana syndrome (Liaw et al, 1997; Marsh et al, 1997;
Nelen et al, 1997).
Transitional cell carcinomas (TCC) of the bladder constitute
two distinct clinical phenotypes. The majority of tumours at
presentation (~80%) are low grade non-invasive lesions which
may recur locally but progress infrequently. In contrast, those
tumours which are muscle invasive at presentation (~20%) often
progress rapidly and have poor prognosis. Previous molecular
genetic analyses have identified LOH on several chromosome
arms including 3p, 4p, 4q, 8p, 9p, 9q, 11p, 13q, 14q, 17p and 18q
in TCC (Presti et al, 1991; Brewster et al, 1994; Knowles
et al, 1994; Chang et al, 1995; Polascik et al, 1995). Apart from
alterations to chromosome 9, all of these changes are more
common in muscle-invasive tumours and to date none, assessed
individually, are good prognostic markers either for superficial
papillary tumours or for tumours that are locally invasive at diag-
nosis. LOH on 10q has been reported to be more frequent in
muscle-invasive TCC (Cappellen et al, 1997). The purpose of
this study was to assess the frequency of LOH at 10q23 and to
determine the frequency of mutation of PTEN in a series of
non-invasive (Ta/T1) and muscle-invasive TCCs.
MATERIALS AND METHODS
Tumours and cell lines
Tumour samples were obtained from patients undergoing
endoscopic resection of bladder carcinoma. Tissues were frozen
immediately at –20°C or in liquid nitrogen and stored at –70°C.
Adjacent portions of each tumour were fixed for histopathological
examination. Tumour grade and stage were assessed according
to the TNM (tumour, node, metastasis) system (UICC, 1978).
Tissues were thawed, dissected and DNA was extracted as
described (Proctor et al, 1991). Some of these DNA samples have
been used in previous published studies of LOH and mutation
analyses in bladder cancer. All have been assessed for LOH at
multiple loci and are believed to contain at least 70% tumour cells
based on these analyses. A venous blood sample was obtained
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from each patient as a source of constitutional DNA, and leucocyte
DNA was extracted (Proctor et al, 1991). The cell lines used were
RT112, RT4, T24, HT1376, HT1197, 253J, 5637, SD, J’ON,
UM-UC-3, VM-CUB-II, SCaBER, J82, SW1710 and 609
(Knowles, 1992).
LOH analysis
Three highly polymorphic microsatellite markers, D10S541,
D10S1765 and  D10S215, were used to assess LOH at 10q23.
These markers map close to PTEN based on physical maps of
the region. Forward primers were labelled with 32P using [g32P]
adenosine 5¢-triphosphate (ATP) and T4 polynucleotide kinase.
Polymerase chain reactions (PCRs) were carried out in 1 ´ PCR
buffer (Perkin-Elmer Corp) with 200 mM deoxynucleotide triphos-
phates, 2 pmol of each primer and 0.125 units of Taq DNA poly-
merase in a total volume of 12.5 ml. Twenty-seven cycles of 95°C
for 1 min, 55°C for 1 min and 72°C for 1.5 min were carried
out followed by an extension at 72°C for 10 min. A total of
7.5 ml loading buffer (95% formamide, 10 mM EDTA, 0.02%
bromophenol blue and 0.02% xylene cyanol) was added, samples
were denatured at 94°C for 5 min and loaded onto 6% denaturing
polyacrylamide gels (National Diagnostics). Following electro-
phoresis, gels were dried and exposed to Fuji RX film for 1–6 h.
LOH was assessed by eye and only cases with clear reduction in
signal from one allele (> 50%) were scored. ‘Partial’ loss of an
allele or ‘allelic imbalance’ was also recorded.
Single-strand conformation polymorphism analysis
Single-strand conformational polymorphism (SSCP) analysis was
carried out as described (Knowles and Williamson, 1993). Gels
consisted of 0.5X mutation detection enhancement solution
(MDE) (FMC BioProducts) and were run at 6–8 watts for 16–18 h
at room temperature. Bands with altered mobility were excised
and eluted from the gels and amplified by PCR using the initial
PCR primers. PCR fragments were isolated by agarose gel elec-
trophoresis and purified for sequencing using the QIAquick Gel
Extraction Kit (Qiagen). Sequencing reactions were carried out
using the ABI PRISM Dye Terminator Cycle Sequencing Kit
(Perkin-Elmer) and the products were analysed on an ABI 377
DNA Sequencer. Sequencing of both strands was carried out using
the initial PCR primers.
Homozygous deletion analysis
Cell line DNAs were used as templates in duplex PCR reactions
with primers for a 300 bp fragment of the enolase gene (ENO,
chromosome 12p) as control (forward primer: TGTGATTCC-
CTCTTTGCTTGCC; reverse primer: TGATCATTCTTCCACG-
GACC). Primer sequences for PTEN are shown in Table 1. PCR
reactions were as for microsatellite analysis but for 30 cycles.
Products were run in 1% agarose gels. DNA from primary tumours
was amplified in duplex reactions containing primers for a
microsatellite marker at which LOH had been detected and
primers for either D10S2491, a CA repeat polymorphism within
PTEN (Cairns et al, 1997), or primers for PTEN exon 8 (8/1F,
8/1R, Table 1). Reactions were as for microsatellite PCR but with
23 cycles. Products were run in 6% denaturing polyacrylamide
gels.
Reverse transcriptase PCR analysis
Total RNA was extracted from cultured cells using RNAzol
(Biogenesis, UK). First-strand cDNA was synthesized using the
Clontech Advantage RT-for-PCR Kit and oligo-dT as primer. Two
pairs of primers were designed to amplify the 5¢ and 3¢ regions of
the cDNA individually. A 5¢ end fragment of 280-bp was ampli-
fied using a forward primer in exon 1 (CATCATCAAAGAGAT-
CGTTAGC) and a reverse primer in exon 5 (TGGGTTA-
TGGTCTTCAAAAGG). A 3¢ fragment of 150-bp was amplified
using a forward primer in exon 8 (GCGTGCAGATAATGA-
CAAGG) and a reverse primer in exon 9(CCTCTGGATT-
TGACGGCTCC). These sequences are conserved in the PTEN
pseudogene (Dahia et al, 1998). cDNA preparations were done in
the presence and absence of reverse transcriptase, the latter acting
as a control for contaminating genomic DNA from which frag-
ments of the pseudogene can be amplified with these primers. No
products were seen in these controls indicating minimal contami-
nation with genomic DNA. Genomic fragments of PTEN are too
large to be amplified by PCR under the conditions used which
consisted of 30 cycles as described above for microsatellite
analysis.
RESULTS
LOH and homozygous deletion at 10q23
A total of 123 bladder tumour samples were analysed for LOH in
the region of the PTEN gene. These comprised 58 muscle invasive
tumours and 65 non-invasive tumours classified as stage Ta or T1
(UICC, 1978). Three markers, D10S541, D10S1765 and D10S215,
which closely flank PTEN, were used. All but ten tumours (five
invasive, five superficial) were informative for at least one
marker. Allelic loss was detected in 13 muscle-invasive tumours
(24.5%) and four superficial tumours (6.6%). An additional four
Table 1 Primers used for SSCP analysis
Exon Primer Sequence Product size
(bp)
1 PTEN1F AGTCGCTGCAACCATCCA
PTEN1R TCTAAGAGAGTGACAGAAAGGTA 319
2 PTEN2F CTGCATATTTCAGATATTTCTTTCC
PTEN2R CTGTGGCTTAGAAATCTTTTC 214
3 PTEN3F CCGTTCGTACGAGAATCGCT
PTEN3R TCTACCTCACTCTAACAAGC 212
4 PTEN4F GGCAATGTTTGTTAGTATTAGTAC
PTEN4R TCGGGTTTAAGTTATACAACATAG 171
5 PTEN5/1F GCAACATTTCTAAAGTTACCTACTTG
PTEN5/1R CATATCATTACACCAGTTCG 236
PTEN5/2F GACAATCATGTTGCAGCAAT
PTEN5/2R CCAATAAATTCTCAGATCCAGG 202
6 PTEN6F TACGACCCAGTTACCATAGC
PTEN6R GAAGGATGAGATTCAAGCAC 254
7 PTEN7F TGGTATGTATTTAACCATGC
PTEN7R CCTTATTTTGGATATTTCTCCC 230
8 PTEN8/1F TGCAAATGTTTAACATAGGTGA
PTEN8/1R CCTTGTCATTATCTGCACGC 244
PTEN8/2F GGAAGTCTATGTGATCAAGA
PTEN8/2R CGTAAACACTGCTTCGAAATA 285
9 PTEN9/1F AGATGAGTCATATTTGTGGG
PTEN9/1R CTAACATCTGGTGTTACAGA 128
PTEN9/2F CGTCAAATCCAGAGGCTAG
PTEN9/2R TCATGGTGTTTTATCCCTCTTG 186906 JS Aveyard et al
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muscle-invasive tumours showed allelic imbalance, which may
indicate either underrepresentation or low level amplification of
one allele. The overall frequency of LOH/allelic imbalance at
10q23 in the muscle-invasive TCCs was, therefore, 32% (Table 2).
Examples are shown in Figure 1.
We also studied a series of 15 bladder cancer cell lines.
Constitutional DNA was available for one of the patients from
whom a cell line was established (J82). This cell line showed LOH
in the PTEN region (data not shown). Since LOH analysis of the
other cell lines was not possible, we carried out duplex PCR
analysis to screen for possible homozygous deletion of PTEN.
PCR was carried out using primers for each exon of PTEN and a
fragment of the enolase gene (ENO) as control. The cell line UM-
UC-3 showed homozygous deletion of all exons of the gene apart
from the 3¢ fragment of exon 9 (9/2 Table 1). Homozygous dele-
tions were also identified in J82 and 609 (Figure 2). Since the
primers for the 3¢ fragment of exon 9 were located within the
PTEN cDNA sequence, the products obtained from these cell lines
may be derived from the PTEN pseudogene. The 3¢ limit of dele-
tion therefore remains to be determined.
To identify possible homozygous deletions of PTEN in tumours
with 10q23 LOH, we carried out duplex PCR on all tumours with
LOH using primers for a CA repeat marker within the PTEN gene
(D10S2491) and primers for a locus at which LOH had been identi-
fied. Using this assay, homozygous deletion of PTEN is indicated if
apparent retention of heterozygosity is detected within the gene in
tumours, with LOH of flanking markers. Homozygous deletion was
detected in one tumour and all other informative tumours showed
clear LOH at D10S2491. Since two of the three cell lines with
homozygous deletion had shown deletion of the 3¢ region of the
gene, we then carried out duplex PCR on seven tumours with clear
LOH at D10S2491 and primers for part of PTEN exon 8. One more
intragenic homozygous deletion was detected by this method.
SSCP and sequence analysis
Intronic primers were designed to amplify the entire coding region
of PTEN in 11 fragments containing all splice junctions (Table 1)
in 63 muscle-invasive tumour samples, including all cases with
LOH/allelic imbalance. Bands with altered mobility were detected
in 13 cases. Altered bands were excised from SSCP gels, re-ampli-
fied and sequenced. Three of these, which were in exon 1, were
also detected in the constitutional DNA of the individual
concerned and were considered likely to be normal sequence poly-
morphisms. Sequencing analysis showed this to be a single base
change (–9C/G). No tumour-specific mutations were detected.
RT-PCR analysis
Seven bladder cell lines (EJ, J82, RT112, RT4, SD, UM-UC-3 and
609) were examined by RT-PCR for expression of PTEN mRNA.
Primers were designed to amplify fragments from the 5¢ and 3¢
ends of the RNA. Results were compatible with the extent of
homozygous deletion identified in the gene. Cell lines with
homozygous deletion showed absence of one or both products and
all other cell lines showed products of the expected size from both
ends of the transcript.
DISCUSSION
We have shown that LOH at 10q23 is found predominantly in
muscle invasive bladder tumours. Our finding of LOH or allelic
imbalance in 32% of tumours ³ pT2 and in only 6.6% of superfi-
cial (Ta/T1) tumours confirms that of Cappellen et al (1997).
This marked tumour stage-associated difference is the likely
N T NT NT N T N T NT
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Figure 1 Examples of LOH at three 10q23 loci in six bladder tumours. N,
leucocyte DNA template; T, tumour DNA template
Table 2 Loss of heterozygosity at 10q23 in transitional cell carcinoma
Marker Frequency of LOH Overall frequency
(LOH/informative cases)
Superficial tumours (Ta/T1)
D10S541 1/33
D10S1765 3/65 4/60 (6.6%)
Invasive tumours (>T2)
D10S215 5/20
D10S541 6/23 13/53 LOH
4/53 allelic imbalance
D10S1765 8/27 Total 17/53 (32%)
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Figure 2 Homozygous deletion of PTEN in bladder tumour cell lines
identified by duplex PCR. (A) Examples of duplex PCR products from the
cell lines UM-UC-3 and 609 with primers for PTEN exons and a 300 bp
fragment of the enolase gene (ENO). Exon 1 is seen as a doublet with ENO
in the 609 sample but is absent from UM-UC-3. (B) Map of homozygous
deletions identified. n Homozygous deletion, n n RetentionPTEN in bladder carcinoma 907
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explanation for the low overall frequencies of 10q deletion found
in some previous studies which examined predominantly superfi-
cial tumours (Knowles et al, 1994; Kallioniemi et al, 1995).
A recent study by Kagan et al (1998) pinpointed a critical region
of LOH at 10q23 in bladder cancer between the loci D10S1644
and D10S541, an interval that contains the PTEN gene. All of the
tumours studied were grade III invasive tumours, 9/20 of which
had discrete deletions focused on this region. PTEN is therefore a
good candidate gene for the target of these deletions in bladder
cancer.
We found no tumour-specific mutations by SSCP analysis in the
panel of 63 muscle-invasive tumours analysed, which included 17
with allelic imbalance at 10q23. Although SSCP does not detect
all mutations, small deletions and insertions and most point muta-
tions should be identified. Indeed, we have identified 18 of 20
known small sequence alterations, including seven point muta-
tions and 11 single or dinucleotide insertion/deletion mutations in
DNA samples from familial cases of tuberous sclerosis (TS) for
which the inactivation was known (DNA kindly provided by
Professor Sue Povey) using the SSCP conditions described here
(Hornigold et al, unpublished results). An advantage of SSCP
analysis on DNA derived from tumour tissues is that mutant
alleles can be identified even in the presence of significant normal
tissue contamination. However, stromal contamination was not a
problem in these samples since LOH was easy to score. Only four
cases showed allelic imbalance rather than clear LOH, which may
indicate higher levels of stromal contamination in a few cases. The
recent report by Cairns et al (1998) that identified only two muta-
tions in a panel of 25 tumours with 10q LOH is in accord with this.
We conclude that small sequence variants of PTEN are rare in
bladder cancer.
The finding of three homozygous deletions of all or part of
PTEN in cell lines and of two homozygous deletions in tumours
suggests that this is a more common mechanism of inactivation.
Similarly, Cairns et al (1998) found four apparent homozygous
deletions in a series of 65 bladder tumours with 10q LOH, and
Teng et al (1997) have reported homozygous deletion of the entire
gene in a bladder tumour cell line. The finding of more frequent
homozygous deletion than small sequence alterations in the
retained allele is reminiscent of the situation for the 9p21 tumour
suppressor gene CDKN2/p16 in which point mutations are infre-
quent but homozygous deletion is more common in bladder
cancer. The type of mutation found may reflect the nature of the
inducing mutagen(s) in a particular tissue or result from other
genetic changes in the tumour concerned. For example, PTEN
point mutations are common in endometrial cancers and particu-
larly those tumours which show microsatellite instability and may
generate single base substitutions at high frequency (Kong et al,
1997).
The frequencies of homozygous deletion and mutation found in
the tumour samples were much lower than the frequency of LOH
in the region. Since we did not map the region of LOH in detail in
these tumours, it is possible that LOH spanned a large part of the
chromosome and the target of this may be another chromosome 10
gene in some cases. The recent results of Kagan et al (1998)
suggest that this is unlikely since most of the deletions they identi-
fied were clustered around PTEN. Fine mapping in the region of
PTEN may clarify this. Our finding of intragenic deletions of
PTEN in cell lines, however, points to this gene as the likely target.
The two small intragenic homozygous deletions in cell lines would
not have been identified using the marker D10S2741, which was
used for the tumour specimens. Since we were able only to use a
non-polymorphic intragenic sequence to examine tumour speci-
mens in the small region deleted in the cell lines, it is possible that
some homozygous deletions were missed in the tumours. It is
likely, therefore, that our finding of only two tumours with
homozygous deletion is an underestimate of the true frequency.
Only accurate assessment of homozygous deletion using carefully
microdissected tumour tissues and multiple intragenic markers
will clarify this.
An alternative explanation for the discrepancy between LOH
frequency and involvement of PTEN is that loss of function of a
single allele may be sufficient to generate an altered phenotype.
Loss of the second allele may contribute at a later step in tumour
progression and, in the case of cell lines, may be selected for
during in vitro establishment. Certainly, several studies of PTEN
have failed to find mutations at the expected frequency, particu-
larly those on prostate and thyroid tumours (Cairns et al, 1997;
Dahia et al, 1997; Pesche et al, 1998).
Finally, recent results that confirm a low frequency of homozy-
gous deletion and mutation in prostate tumour xenografts (Whang
et al, 1998) suggest that PTEN may be transcriptionally silenced in
some cases by hypermethylation. Examination of the methylation
status of the retained PTEN allele in bladder tumours with LOH
must now be carried out.
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